Intermedin (IMD) is a new type of cardiovascular regulatory peptide found in recent years. It is a new member of calciton gene related peptide (CGRP). Previous studies have found that the IMD has important protective effect in ischemia reperfusion. Epidemiological and clinical studies have shown that diabetic population of ischemic heart disease (angina and myocardial infarction), congestive heart failure and the incidence of atherosclerotic lesions caused by disease and its severity is much higher than people without diabetes. Therefore, it remains to be discussed whether the IMD has protective effect in diabetic patients with coronary heart disease. This article reviews the biological characteristics of the IMD and its role in diabetic patients combined with coronary heart disease from basic research to clinical research progress.